Clinical trials: Chemotherapy-Induced Nausea and Vomiting (CINV)
Nausea With Vomiting Chemotherapy-Induced
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Phase 2 study to compare efficacy, safety and PK of palonosetron, a long acting 5-HT3 receptor antagonist, by buccal film delivery compared to iv injection for chemotherapy induced nausea or vomiting (CINV).
- Trial name
- NCT04592198
- Testing
- Palonosetron Hydrochloride Buccal Film 0.25 Mg, Palonosetron Hydrochloride Buccal Film 0.5 Mg, Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Xiamen LP Pharmaceutical Co., Ltd
Nausea, Vomiting
Auriculotherapy and Acupuncture's Treatment for Chemotherapy-induced Nausea and Vomiting (CINV)
The management of chemotherapy-induced nausea and vomiting (CINV) has evolved in recent years and became less frequent. CINV include early (occurring within 24 hours of chemotherapy administration) and delayed (occurring within 4…
- Trial name
- NVCI (NCT02767791)
- Testing
- Acupuncture, Auriculotherapy
- Where
- 5 sites in France
- Volunteers
- 116 people
- Sponsor
- Hopital Foch
Malignant Neoplasm
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
This phase II trial studies how well netupitant and palonosetron hydrochloride work in preventing chemotherapy induced nausea and vomiting in patients with cancer undergoing BEAM conditioning regimen before stem cell transplant.
- Trial name
- NCT03097588
- Testing
- Netupitant, Palonosetron Hydrochloride, Questionnaire Administration
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- OHSU Knight Cancer Institute
Chemotherapy Induced Nausea and Vomiting
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 6 to 12 years.
- Trial name
- NCT01596413
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Chemotherapy-induced Nausea and Vomiting
An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC
This prospective, multicenter, non-comparative, open-label trial design aims to evaluate the efficacy and safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in preventing nausea and vomiting induced by…
- Trial name
- NCT07482891
- Testing
- Fosrolapitant and Palonosetron Hydrochloride for Injection, Dexamethasone, Olanzapine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai 6th People's Hospital
Chemotherapy Induced Nausea Vomiting
Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory CINV
Prevention and control of Chemotherapy-Induced Nausea and Vomiting (CINV) are most important in treatment of cancer patients. CINV is one of the most distressing severe side effects of cancer treatment and can have a significant…
- Trial name
- CINV (NCT03008213)
- Testing
- Netupitant and Palonosetron
- Volunteers
- 4 people
- Sponsor
- Joseph Ma
Chemotherapy-induced Nausea and Vomiting
Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants
The purpose of this research study is to see if olanzapine helps to prevent nausea and/or vomiting (throwing up) when it is added to other medicines in subjects having stem cell transplants.
- Trial name
- NCT04535141
- Testing
- Olanzapine 5 MG
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Chemotherapy-induced Nausea and Vomiting
Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)
The purpose of this study is to evaluate the use of aromatherapy to reduce nausea, vomiting, and the use of anti-emetic in cancer survivors undergoing moderate to highly emetogenic chemotherapy regimens.
- Trial name
- NCT05319860
- Testing
- Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV), Aromatherapy Care
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Chemotherapy often causes nausea and vomiting (CINV), and this is a major problem for the children being treated for cancer. To prevent this, a combination of two substances in fixed proportion (IV NEPA) was developed.
- Trial name
- NCT06904235
- Testing
- IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion, Reference Treatment: IV fosaprepitant infusion
- Where
- 20 sites in Greece, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Helsinn Healthcare SA
Breast Cancer, Malignant Female Reproductive System Neoplasm
Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting
This randomized controlled three arm study compares the effects of a yoga intervention with jacobsons progressive muscle relaxation training and only standard of care in chemotherapy naive cancer patients.
- Conditions
- Breast Cancer, Malignant Female Reproductive System Neoplasm, Lymphomas, Chemotherapy-induced Nausea and Vomiting
- Trial name
- NCT01387841
- Testing
- yoga, Jacobsons PMRT group
- Where
- India
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Bharath Charitable Cancer Hospital and Institute
Chemotherapy Induced Nausea and Vomiting
Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
The primary purpose of the study is to determine the efficacy of oral dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting (CINV) or retching by measuring…
- Trial name
- NCT00642512
- Testing
- dronabinol, ondansetron, dronabinol/ondansetron
- Where
- 43 sites in United States
- Volunteers
- 64 people
- Sponsor
- Solvay Pharmaceuticals
Chemotherapy-induced Nausea and Vomiting
Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV
Nausea and vomiting caused by chemotherapy are considered by patients as the main side effects of cancer treatment, which affect the quality of treatment and life.At present, NCCN guidelines have recommended three or four drug…
- Trial name
- NCT05805800
- Testing
- 5HT3RA+Olanzapine, 5HT3RA+Olanzapine+Dexamethasone
- Where
- China
- Volunteers
- 275 people
- Sponsor
- Xingchen Peng
Chemotherapy-induced Nausea and Vomiting
Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting
Chemotherapy-induced nausea and vomiting (CINV) adversely affects patients' quality of life and may affect patients' treatment decisions.
- Trial name
- NCT04085393
- Testing
- GRANISETRON EXTENDED RELEASE INJECTION (GERSC)
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Nausea, Vomiting
Laser Acupuncture Against Nausea in Children
To investigate whether nonthermal low level laser acupuncture has beneficial effects on nausea and vomiting in children receiving highly emetogenic chemotherapy for a malignant solid tumor.
- Conditions
- Nausea, Vomiting, Cancer
- Trial name
- NCT00528554
- Testing
- laser acupuncture
- Where
- 2 sites in Germany
- Volunteers
- 25 people
- Sponsor
- University Children Hospital Homburg
Chemotherapy-induced Nausea and Vomiting
Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.
- Trial name
- CINV (NCT04817189)
- Testing
- NEPA (300mg netupitant/0.5mg palonosetron), Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), Dexamethasone, 8 mg (oral) or equivalent IV dose
- Where
- 19 sites in China, Czechia and 5 more
- Volunteers
- 414 people
- Sponsor
- Helsinn Healthcare SA
Colorectal Cancer
Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial
The object of this study is to evaluate the superiority of aprepitant therapy with a 5HT3-receptor antagonist, dexamethasone and aprepitant compared to standard therapy with a 5HT3-receptor antagonist and dexamethasone for…
- Trial name
- NCT01344304
- Testing
- Aprepitant / Fosaprepitant
- Where
- 27 sites in Japan
- Volunteers
- 413 people
- Sponsor
- Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
Chemotherapy-induced Nausea and Vomiting
The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy
This is a pragmatic randomized, multi-center, open-label randomized clinical trial, aimed to evaluate efficacy and safety of thalidomide in improving prevention of chemotherapy-induced delayed nausea and vomiting (CINV) in…
- Trial name
- NCT03601871
- Testing
- Thalidomide, Dexamethasone, 5-HT3 antagonists
- Where
- 29 sites in China
- Volunteers
- 880 people
- Sponsor
- Yunpeng Liu
Nausea and Vomiting, Chemotherapy-Induced
A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
This is a Phase III trial designed to demonstrate that casopitant when added to dexamethasone and ondansetron is more effective in the prevention of vomiting then dexamethasone and ondansetron alone, in patients who receive a…
- Trial name
- NCT00431236
- Testing
- Oral Casopitant (GW679769), IV Casopitant (GW679769), IV ondansetron hydrochloride
- Where
- 80 sites in Argentina, Belgium and 20 more
- Volunteers
- 810 people
- Sponsor
- GlaxoSmithKline
Chemotherapy-Induced Nausea and Vomiting
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
The study will test aprepitant for the prevention of CINV in patients receiving their initial cycle of Moderately Emetogenic Chemotherapy (MEC).
- Trial name
- NCT00337727
- Testing
- aprepitant, Comparator: ondansetron, Comparator: dexamethasone
- Volunteers
- 848 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myelogenous Leukemia, Chemotherapy-induced Nausea and Vomiting
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
The goal of this clinical research study is to compare the effectiveness of 3 drug schedules in preventing chemotherapy-related nausea and/or vomiting in patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic…
- Trial name
- NCT01031498
- Testing
- Ondansetron, Palonosetron
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center